ViCentra, an Utrecht-based medical device company innovating insulin delivery for people with diabetes, announced the successful close of a €72.4 million Series D financing to accelerate manufacturing and launch the Kaleido 2 patch pump in Europe while preparing for US market entry.
The round was led by new investor Innovation Industries, a DeepTech VC firm, with matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from EQT Life Sciences and Health Innovations.
“Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honors those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.
Founded in 2013, ViCentra’s mission is to improve life with diabetes through empathetic innovation, simplicity, and design excellence. The company develops and manufactures the Kaleido insulin patch pump system, an alternative to traditional insulin pumps. Headquartered in Utrecht, the Netherlands, ViCentra is expanding across Europe and preparing for U.S. market entry.
Designed to feel more like personal technology than a traditional medical device, users can select their own aluminum shells from a range of ten preset colour options. Integrated with Diabeloop’s self-learning automated insulin delivery algorithm and compatible with the Dexcom CGM sensor, Kaleido aims to position ViCentra at the forefront of next-generation diabetes care, helping reach many more users and improve the quality of life for people with diabetes.
Strong initial commercial uptake of Kaleido in Germany, France, and the Netherlands has driven demand beyond initial expectations.
“ViCentra is redefining insulin pump therapy with a platform that truly centers the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries.
The global insulin delivery market is reportedly one of the largest and fastest growing medical device segments, driven by the rising prevalence of diabetes and increasing demand for solutions that blend clinical effectiveness with everyday usability.
According to data provided by ViCentra, the insulin pump market alone is projected to reach over €11.9 billion by 2034. Patch pumps represent the fastest-growing segment of the insulin delivery market, signaling a broader industry shift toward compact, wearable, and patient-centric solutions.
“At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We’re proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry,” added Greebe.
Read the orginal article: https://www.eu-startups.com/2025/09/dutch-medtech-startup-vicentra-raises-e72-4-million-to-scale-their-kaleido-insulin-patch-pump/
